Evidence map›Paper›PMID 35429393›Full record

ArticleTranslational behavioral medicine2022

Motivating cascade testing for familial hypercholesterolemia: applying the extended parallel process model for clinician communication.

Gemme Campbell-Salome, Nicole L Walters, Ilene G Ladd, Amanda Sheldon, Catherine Davis Ahmed, Andrew Brangan, Megan N McMinn, Alanna K Rahm, Marci L B Schwartz, Eric Tricou and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Translational behavioral medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 12 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Gemme Campbell-SalomeGenomic Medicine Institute, Geisinger, Danville, PA, USA.ORCID 0000-0003-1377-5705
Nicole L WaltersGenomic Medicine Institute, Geisinger, Danville, PA, USA.
Ilene G LaddGenomic Medicine Institute, Geisinger, Danville, PA, USA.
Amanda SheldonThe FH Foundation, Pasadena, CA, USA.
Catherine Davis AhmedThe FH Foundation, Pasadena, CA, USA.
Andrew BranganGenomic Medicine Institute, Geisinger, Danville, PA, USA.
Megan N McMinnGenomic Medicine Institute, Geisinger, Danville, PA, USA.
Alanna K RahmGenomic Medicine Institute, Geisinger, Danville, PA, USA.
Marci L B SchwartzGenomic Medicine Institute, Geisinger, Danville, PA, USA.
Eric TricouGenomic Medicine Institute, Geisinger, Danville, PA, USA.
Carla L FisherCollege of Journalism and Communications, University of Florida, Gainesville, FL, USA.ORCID 0000-0003-3903-4278
Amy C SturmGenomic Medicine Institute, Geisinger, Danville, PA, USA.
FH Foundation · USUniversity of Florida · USGeisinger Neuroscience Institute · US

Funding

Identification Methods, Patient Activation, and Cascade Testing for FH: IMPACT-FHR01HL148246 · NHLBI · GEISINGER CLINIC · PI Ana Morales Reyes · 2019 to 2026
$5.2M
NHLBI NIH HHSNHLBI NIH HHS R01 HL148246NIH HHS RO1HL148246
6 · The paper itself

Abstract

Motivating at-risk relatives to undergo cascade testing for familial hypercholesterolemia (FH) is critical for diagnosis and lifesaving treatment. As credible sources of information, clinicians can assist in family communication about FH and motivate cascade testing uptake. However, there are no guidelines regarding how clinicians should effectively communicate with probands (the first person diagnosed in the family) and at-risk relatives. Individuals and families with FH can inform our understanding of the most effective communications to promote cascade testing. Guided by the extended parallel process model (EPPM), we analyzed the perspectives of individuals and families with FH for effective messaging clinicians can use to promote cascade testing uptake. We analyzed narrative data from interviews and surveys collected as part of a larger mixed-methods study. The EPPM was used to identify message features recommended by individuals and families with FH that focus on four key constructs (severity, susceptibility, response efficacy, self-efficacy) to promote cascade testing. Participants included 22 individuals from 11 dyadic interviews and 98 survey respondents. Participants described prioritizing multiple messages that address each EPPM construct to alert relatives about their risk. They illustrated strategies clinicians could use within each EPPM construct to communicate to at-risk relatives about the importance of pursuing diagnosis via cascade testing and subsequent treatment for high cholesterol due to FH. Findings provide guidance on effective messaging to motivate cascade testing uptake for FH and demonstrates how the EPPM may guide communication with at-risk relatives about genetic risk and motivate cascade testing broadly.

Indexed as

Genetic TestingHyperlipoproteinemia Type IICommunicationHumansRisk FactorsCascade testingextended parallel process modelFamilial hypercholesterolemiaGenetic testingHealth communicationRisk communication

Identifiers

PMID35429393
PMCPMC9291357
OpenAlexW4223971629

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.